Judul

Usulan Penelitian untuk Tesis S-2

Minat Utama Biologi Molekuler & Imunologi Penyakit Tropis

Program Magister Studi Ilmu Kedokteran Tropis



Diajukan oleh

Nama

NIM:

Kepada

PROGRAM PASCASARJANA ILMU KEDOKTERAN TROPIS

FAKULTAS KEDOKTERAN, KESEHATAN MASYARAKAT, DAN KEPERAWATAN

UNIVERSITAS GADJAH MADA

YOGYAKARTA

Desember 2021

PROPOSAL PENELITIAN

Judul

yang diajukan oleh

Nama

NIM:

Telah disetujui oleh:

Pembimbing Utama

_____ Tanggal…….....

Pembimbing Pendamping I

_____ Tanggal…….....

DAFTAR ISI

Halaman Judul
Daftar Isi

BAB I PENDAHULUAN
A. Latar Belakang ……..... 5
B. Perumusan Masalah ……..... 8
C. Tujuan Penelitian ……. 8
D. Keaslian Penelitian …….. 9
E. Manfaat Penelitian ……... 10

BAB II TINJAUAN PUSTAKA
A. Tinjauan Pustaka ……. 11
1. Epidemiologi Tuberkulosis ……..……..…… 11
2. Respon Imun Tubuh terhadap *Mycobacterium tuberculosis* ……. 14
a. Respon Imun Bawaan (*Innate Immune Response*) ……. 15
b. Respon Imun Adaptif (*Adaptive Immune Response*) …….. 17
3. Faktor Virulensi *Mycobacterium tuberculosis* …….. 23
a. ESAT-6 dan CFP-10 ……... 24
b. Kompleks Ag85...……... 24
c. Resistensi Rifampicin Pada *Mycobacterium tuberculosis*…… 26
d. Isolat *Multidrug-Resistant Mycobacterium tuberculosis*
4. Diagnosis Tuberkulosis ……. 26
a. *Tuberculin Skin Test* (TST) …… 27
b. *Interferon Gamma Release Assay* (IGRA) ……. 28
c. Xpert MTB/ RIF Assay …….. 29
5. Biomarker yang Berpotensi untuk Diagnosa Tuberkulosis ……...…….... 30
a. Biomarker untuk TB Aktif & LTBI ……...
b. Biomarker untuk MDR-TB ……...
6. *Flow Cytometry* ……..… 32
7. *Enzyme Linked Immunosorbent Assay* (ELISA) ……..…. 33
8. Mencit (Mus musculus) Galur Balb/c sebagai Hewan Coba Penelitian Respon Imun ……..
B. Landasan Teori …… 34
C. Kerangka Teoritis …… 36
D. Kerangka Konsep …… 37
E. Hipotesis …….. 37

BAB III METODE PENELITIAN
A. Jenis dan Rancangan Penelitian ……... 38
B. Lokasi & Waktu Penelitian …….. 38
C. Subjek Penelitian ……. 39
1. Sampel Penelitian …….. 39

2. Teknik Pengambilan Sampel …… 39
D. Variabel Penelitian …….. 39
E. Definisi Operasional ……..... 40
F. Bahan dan Alat Penelitian ……... 41
G. Prosedur Penelitian …….. 42
H. Alur Penelitian ……. 49

I. Analisis Hasil ……..……. 50
J. Jadual Penelitian …….. 51

DAFTAR PUSTAKA …… 52

BAB I

PENDAHULUAN

A. Latar Belakang

B. Perumusan Masalah

C. Tujuan Penelitian

D. Keaslian Penelitian

E. Manfaat Penelitian

1. Manfaat teoritis

2. Manfaat praktis

BAB II

TINJAUAN PUSTAKA

A. Tinjauan Pustaka

B. Landasan Teori

C. Kerangka Teoriti

D. Kerangka Konsep

E. Hipotesis

BAB III

METODE PENELITIAN

A. Jenis dan Rancangan Penelitian

B. Lokasi dan Waktu Penelitian

C. Subjek Penelitian

D. Variabel Penelitian

E. Definisi Operasional

F. Bahan dan Alat Penelitian

G. Prosedur Penelitian

H. Alur Penelitian

I. Analisis Hasil

J. Jadual Penelitian

DAFTAR PUSTAKA

Agustin, H. *et al.* (2021) 'Analysis of CD4 and CD8 expression in multidrug-resistant tuberculosis infection with diabetes mellitus: An experimental study in mice', *Annals of Medicine and Surgery*, 68(July), p. 102596. doi: 10.1016/j.amsu.2021.102596.

Al-Mutairi, N. M. *et al.* (2019) 'Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis', *BMC Infectious Diseases*, 19(1), pp. 1–9. doi: 10.1186/s12879-018-3638-z.

Arlehamn, C. L. *et al.* (2014) 'Transcriptional Profile of Tuberculosis Antigen–Specific T Cells Reveals Novel Multifunctional Features', *The Journal of Immunology*, 193(6), pp. 2931–2940. doi: 10.4049/jimmunol.1401151.

Arlehamn, C. S. L. *et al.* (2014) 'in Tuberculosis', pp. 1–15.

Babaki, M. K. Z., Soleimanpour, S. and Rezaee, S. A. (2017) 'Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: Biology, immune-pathogenicity, applications in diagnosis, and vaccine design', *Microbial Pathogenesis*, 112, pp. 20–29. doi: 10.1016/j.micpath.2017.08.040.

Beery, A. K. (2018) 'Inclusion of females does not increase variability in rodent research studies', *Current Opinion in Behavioral Sciences*, 23, pp. 143–149. doi: 10.1016/j.cobeha.2018.06.016.

Bentwich, Z. (2005) 'CD4 measurements in patients with HIV: Are they feasible for poor settings?', *PLoS Medicine*, 2(7), pp. 0595–0596. doi: 10.1371/journal.pmed.0020214.

Carranza, C. *et al.* (2020) 'Diagnosis for Latent Tuberculosis Infection: New Alternatives', *Frontiers in Immunology*, 11(September), pp. 1–13. doi: 10.3389/fimmu.2020.02006.

Cavalcanti, Y. V. N. *et al.* (2012) 'Role of TNF-alpha, IFN-gamma, and IL-10 in the development of pulmonary tuberculosis', *Pulmonary Medicine*, 2012. doi: 10.1155/2012/745483.

Chakaya, J. *et al.* (2021) 'Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts', *International Journal of Infectious Diseases*, (xxxx), pp. 4–9. doi: 10.1016/j.ijid.2021.02.107.

Chen, J. *et al.* (2020) 'Serum sCD14, PGLYRP2 and FGA as potential biomarkers for multidrug-resistant tuberculosis based on data-independent acquisition and targeted proteomics', *Journal of Cellular and Molecular Medicine*, 24(21), pp. 12537–12549. doi: 10.1111/jcmm.15796.

Chileshe, J. *et al.* (2019) 'A commercial ELISA for detection of interferon gamma in white rhinoceros', *Journal of Veterinary Diagnostic Investigation*, 31(4), pp. 531–536. doi: 10.1177/1040638719843955.

Christianto, D. *et al.* (2019) 'Efek Pemberian Protein Rekombinan Fusi ESAT6-CFP10 Mycobacterium tuberculosis terhadap Persentase IL2 dan IL10 yang Dipresentasikan Sel T CD8 pada Kultur PBMC Effect of Mycobacterium tuberculosis ' s ESAT6-CFP10 Recombinant Fusion Protein Addition on IL2', *Jurnal Kedokteran Brawijaya*, 30(3), pp. 202–208.

Division of Tuberculosis Elimination (2013) 'A New Tool to Diagnose Tuberculosis : The Xpert MTB / RIF Assay', *Cdc*, p. 2.

Favrot, L. *et al.* (2013) 'Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen', *Nature Communications*, 4(May). doi: 10.1038/ncomms3748.

Fihiruddin *et al.* (2020) 'Cloning, expression and T cell epitope prediction of fbpa and fbpb genes of mycobacterium tuberculosis clinical isolates', *Journal of Microbiology, Biotechnology and Food Sciences*, 9(5), pp. 998–1002. doi: 10.15414/jmbfs.2020.9.5.998-1002.

Fihiruddin, F. *et al.* (2019) 'Expression of Immunoglobulin, Granzyme-B, and Perforin Against Ag85A and Ag85B of Mycobacterium Tuberculosis in Balb/c Mice', *African Journal Infection Disease*, 13, pp. 13–20.

Garcia-Pelayo, M. C. *et al.* (2015) 'BALB/c mice display more enhanced BCG vaccine induced Th1 and Th17 response than C57BL/6 mice but have equivalent protection', *Tuberculosis*, 95(1), pp. 48–53. doi: 10.1016/j.tube.2014.10.012.

Garcia-Rodriguez, K. M. *et al.* (2017) 'The role of mast cells in tuberculosis: Orchestrating innate immune crosstalk?', *Frontiers in Immunology*, 8(OCT), pp. 1–8. doi: 10.3389/fimmu.2017.01290.

Goletti, D. *et al.* (2016) 'Tuberculosis biomarkers: From diagnosis to protection', *Infectious Disease Reports*, 8(2), pp. 24–32. doi: 10.4081/idr.2016.6568.

Hertz, D. *et al.* (2020) 'Increased male susceptibility to Mycobacterium tuberculosis infection is associated with smaller B cell follicles in the lungs', *Scientific Reports*, 10(1), pp. 1–9. doi: 10.1038/s41598-020-61503-3.

Huang, H. *et al.* (2018) 'Rifampicin Resistance and Multidrug-Resistant Tuberculosis Detection Using Xpert MTB/RIF in Wuhan, China: A Retrospective Study', *Microbial Drug Resistance*, 24(5), pp. 675–679. doi: 10.1089/mdr.2017.0114.

Huang, H. *et al.* (2020) 'The novel potential biomarkers for multidrug-resistance tuberculosis using UPLC-Q-TOF-MS', *Experimental Biology and Medicine*, 245(6), pp. 501–511. doi: 10.1177/1535370220903464.

Hur, Y. G. *et al.* (2015) 'Adjunctive biomarkers for improving diagnosis of tuberculosis and monitoring therapeutic effects', *Journal of Infection*, 70(4), pp. 346–355. doi: 10.1016/j.jinf.2014.10.019.

Kemenkes, R. (2021) *Situasi Tuberkulosis Indonesia Tahun 2020*, *Data TBC pada tanggal 16 April 2021*. Available at: https://tbindonesia.or.id/pustaka-tbc/dashboard-tb/ (Accessed: 28 September 2021).

Kisuya, J. *et al.* (2019) 'The diagnostic accuracy of Th1 (IFN-γ, TNF-α, and IL-2) and Th2 (IL-4, IL-6 and IL-10) cytokines response in AFB microscopy smear negative PTB- HIV co-infected patients', *Scientific Reports*, 9(1), pp. 1–12. doi: 10.1038/s41598-019-39048-x.

Konstantinou and N., G. (2017) 'Food Allergens: Methods and Protocols', *EUFIC review*, 1592, pp. 1–299. doi: 10.1007/978-1-4939-6925-8.

Lawn, S. D. and Nicol, M. P. (2011) 'Xpert MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance', *Future Microbiology*, 6(9), pp. 1067–1082. doi: 10.2217/FMB.11.84.

Leary, S. *et al.* (2013) *AVMA Guidelines for the Euthanasia of Animals: 2013 Edition*, *American Veterinary Medical Association*. doi: 10.1016/B978-012088449-0.50009-1.

Lee, J. Y. *et al.* (2015) 'Immune parameters differentiating active from latent tuberculosis infection in humans', *Tuberculosis*, 95(6), pp. 758–763. doi: 10.1016/j.tube.2015.08.003.

Leem, A. Y. *et al.* (2018) 'Changes in cytokine responses to TB antigens ESAT-6, CFP-10 and TB 7.7 and inflammatory markers in peripheral blood during therapy', *Scientific Reports*, 8(1), pp. 4–11. doi: 10.1038/s41598-018-19523-7.

Li, K. *et al.* (2020) 'Changes in T-lymphocyte subsets and risk factors in human immunodeficiency virus-negative patients with active tuberculosis', *Infection*, 48(4), pp. 585–595. doi: 10.1007/s15010-020-01451-2.

Maphasa, R. E., Meyer, M. and Dube, A. (2021) 'The Macrophage Response to Mycobacterium tuberculosis and Opportunities for Autophagy Inducing Nanomedicines for Tuberculosis Therapy', *Frontiers in Cellular and Infection Microbiology*, 10(February), pp. 1–22. doi: 10.3389/fcimb.2020.618414.

Marín, N. D. *et al.* (2013) 'Functional profile of CD4+ and CD8+ T cells in latently infected individuals and patients with active TB', *Tuberculosis*, 93(2), pp. 155–166. doi: 10.1016/j.tube.2012.12.002.

de Martino, M. *et al.* (2019) 'Immune Response to Mycobacterium tuberculosis: A Narrative Review', *Frontiers in Pediatrics*, 7(August), pp. 1–8. doi:

10.3389/fped.2019.00350.

McKinnon, K. M. (2018) 'Flow cytometry: An overview', *Current Protocols in Immunology*, 2018(February), pp. 5.1.1-5.1.11. doi: 10.1002/cpim.40.

McNerney, R. *et al.* (2012) 'Tuberculosis diagnostics and biomarkers: Needs, challenges, recent advances, and opportunities', *Journal of Infectious Diseases*, 205(SUPPL. 2), pp. 147–158. doi: 10.1093/infdis/jir860.

Mehta, P. K. *et al.* (2017) 'Immuno-PCR, a new technique for the serodiagnosis of tuberculosis', *Journal of Microbiological Methods*, 139, pp. 218–229. doi: 10.1016/j.mimet.2017.05.009.

Mertaniasih, N. M. *et al.* (2016) 'Sequence Analysis of the Gene Region Encoding ESAT-6, Ag85B, and Ag85C Proteins from Clinical Isolates of Mycobacterium tuberculosis', *Procedia Chemistry*, 18(Mcls 2015), pp. 225–230. doi: 10.1016/j.proche.2016.01.035.

Miggiano, R., Rizzi, M. and Ferraris, D. M. (2020) 'Mycobacterium tuberculosis pathogenesis, infection prevention and treatment', *Pathogens*, 9(5), pp. 10–13. doi: 10.3390/pathogens9050385.

Mihret, A. (2012) 'The role of dendritic cells in Mycobacterium tuberculosis infection', *Virulence*, 3(7), pp. 654–659. doi: 10.4161/viru.22586.

Millington, K. A. *et al.* (2007) ' Dynamic Relationship between IFN-γ and IL-2 Profile of Mycobacterium tuberculosis -Specific T Cells and Antigen Load ', *The Journal of Immunology*, 178(8), pp. 5217–5226. doi: 10.4049/jimmunol.178.8.5217.

Nakamura, H. (2013) *BALB/c Mouse*, *Brenner's Encyclopedia of Genetics: Second Edition*. Elsevier Inc. doi: 10.1016/B978-0-12-374984-0.00133-9.

Nieuwenhuizen, N. E. *et al.* (2021) 'Weaker protection against tuberculosis in BCG-vaccinated male 129 S2 mice compared to females', *Vaccine*, 39(50), pp. 7253–7264. doi: 10.1016/j.vaccine.2021.09.039.

Nikolova, M. *et al.* (2013a) 'Antigen-specific CD4- and CD8-positive signatures in different phases of Mycobacterium tuberculosis infection', *Diagnostic Microbiology and Infectious Disease*, 75(3), pp. 277–281. doi: 10.1016/j.diagmicrobio.2012.11.023.

Nikolova, M. *et al.* (2013b) 'Antigen-specific CD4- and CD8-positive signatures in different phases of Mycobacterium tuberculosis infection', *Diagnostic Microbiology and Infectious Disease*, 75(3), pp. 277–281. doi: 10.1016/j.diagmicrobio.2012.11.023.

O'Garra, A. *et al.* (2013) *The immune response in tuberculosis*, *Annual Review of Immunology*. doi: 10.1146/annurev-immunol-032712-095939.

Ocaña-Guzmán, R. *et al.* (2021) 'Leukocytes from Patients with Drug-Sensitive and Multidrug-Resistant Tuberculosis Exhibit Distinctive Profiles of

Chemokine Receptor Expression and Migration Capacity', *Journal of Immunology Research*, 2021. doi: 10.1155/2021/6654220.

OCPHO (2014) *NWT Tuberculosis Manual*. Northwest Territories Health and Social Services. Available at: https://www.hss.gov.nt.ca/professionals/en/services/nwt-tuberculosis-manual.

Palomino, J. C. and Martin, A. (2014) 'Drug resistance mechanisms in Mycobacterium tuberculosis', *Antibiotics*, 3(3), pp. 317–340. doi: 10.3390/antibiotics3030317.

Peng, X. and Sun, J. (2016) 'Mechanism of ESAT-6 membrane interaction and its roles in pathogenesis of Mycobacterium tuberculosis', *Toxicon*, 116, pp. 29–34. doi: 10.1016/j.toxicon.2015.10.003.

Petruccioli, E. *et al.* (2016) 'First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus', *Journal of Infection*, 73(6), pp. 588–597. doi: 10.1016/j.jinf.2016.09.008.

Pollock, K. M. *et al.* (2013) 'T-cell immunophenotyping distinguishes active from latent tuberculosis.', *The Journal of infectious diseases*, 208(6), pp. 952–968. doi: 10.1093/infdis/jit265.

Prezzemolo, T. *et al.* (2014) 'Functional signatures of human CD4 and CD8 T cell responses to Mycobacterium tuberculosis', *Frontiers in Immunology*, 5(APR), pp. 1–13. doi: 10.3389/fimmu.2014.00180.

Qiao, D. *et al.* (2011) 'Mycobacterium tuberculosis culture filtrate protein 10-specific effector/memory CD4+ and CD8+ T cells in tubercular pleural fluid, with biased usage of T cell receptor Vβ Chains', *Infection and Immunity*, 79(8), pp. 3358–3365. doi: 10.1128/IAI.00014-11.

Rosano, G. L. and Ceccarelli, E. A. (2014) 'Recombinant protein expression in Escherichia coli: Advances and challenges', *Frontiers in Microbiology*, 5(APR), pp. 1–17. doi: 10.3389/fmicb.2014.00172.

Ruhwald, M. *et al.* (2017) 'Introducing the ESAT-6 free IGRA, a companion diagnostic for TB vaccines based on ESAT-6', *Scientific Reports*, 7(March), pp. 1–10. doi: 10.1038/srep45969.

Sellers, R. S. *et al.* (2012) 'Immunological variation between inbred laboratory mouse strains: Points to consider in phenotyping genetically immunomodified mice', *Veterinary Pathology*, 49(1), pp. 32–43. doi: 10.1177/0300985811429314.

Shi, W. *et al.* (2019) 'Plasma indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant tuberculosis in tuberculosis patients', *Infection and Drug Resistance*, 12, pp. 1265–1276. doi: 10.2147/IDR.S202369.

Sudbury, E. L. *et al.* (2019) 'Mycobacterium tuberculosis-specific cytokine biomarkers for the diagnosis of childhood TB in a TB-endemic setting', *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, 16, p. 100102. doi: 10.1016/j.jctube.2019.100102.

Tan, Q. *et al.* (2017) 'Clinical and Immunological Effects of rhIL-2 Therapy in Eastern Chinese Patients with Multidrug-resistant Tuberculosis', *Scientific Reports*, 7(1), pp. 1–11. doi: 10.1038/s41598-017-18200-5.

Tan, Yaoju *et al.* (2021) 'Combined IFN-γ and IL-2 release assay for detect active pulmonary tuberculosis: a prospective multicentre diagnostic study in China', *Journal of Translational Medicine*, 19(1), pp. 1–8. doi: 10.1186/s12967-021-02970-8.

Walzl, G. *et al.* (2011) 'Immunological biomarkers of tuberculosis', *Nature Reviews Immunology*, 11(5), pp. 343–354. doi: 10.1038/nri2960.

WHO (2019) *Consolidated Guidelines on Tuberculosis Treatment*, *Who*. Available at: https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/.

Wibowo, R. Y., Tambunan, B. A. and Nugraha, J. (2017) 'Ekspresi IFN-Gamma oleh Sel T CD4 + dan CD8 + Setelah Stimulasi Antigen Fusi ESAT-6-CFP-10 pada Pasien Tuberkulosis Paru Aktif', *Buletin Penelitian Kesehatan*, 45(4), pp. 223–226. doi: 10.22435/bpk.v45i4.6874.223-226.

Wolday, D. *et al.* (2020) 'Role of CD4/CD8 ratio on the incidence of tuberculosis in HIV-infected patients on antiretroviral therapy followed up for more than a decade', *PLoS ONE*, 15(5), pp. 1–15. doi: 10.1371/journal.pone.0233049.

Yang, J. D. *et al.* (2018) 'Mycobacterium tuberculosis-specific CD4+and CD8+T cells differ in their capacity to recognize infected macrophages', *PLoS Pathogens*, 14(5), pp. 1–30. doi: 10.1371/journal.ppat.1007060.

Yang, T. and Ge, B. (2018) 'miRNAs in immune responses to Mycobacterium tuberculosis infection', *Cancer Letters*, 431(May), pp. 22–30. doi: 10.1016/j.canlet.2018.05.028.

Yang, Y. and Wu, J. (2019) 'Significance of the differential peptidome in multidrug-resistant tuberculosis', *BioMed Research International*, 2019. doi: 10.1155/2019/5653424.

Yong, Y. K. *et al.* (2019) 'Immune Biomarkers for Diagnosis and Treatment Monitoring of Tuberculosis: Current Developments and Future Prospects', *Frontiers in Microbiology*, 10(December). doi: 10.3389/fmicb.2019.02789.